About

Dr. Peter Blume-Jensen is Acrivon's main founder and has served as its Chief Executive Officer, acting Chief Scientific Officer and President since March 2018 and as Chairman of the Board since October 2020. He is the inventor of the founding AP3 (Acrivon Predictive Precision Proteomics) platform and the OncoSignature patient-selection method. He previously served as Chief Scientific Officer at XTuit Pharmaceuticals and at Metamark Genetics, as Vice President and Global Therapeutic Area Advisor for Oncology at Daiichi Sankyo, and as a department head at Merck & Co. and Serono, US. His review 'Oncogenic Kinase Signaling' (Nature, 2001) is a citation classic in clinical medicine. Dr. Blume-Jensen received his M.D. from Copenhagen University Medical School, his Ph.D. from the Ludwig Institute for Cancer Research in Uppsala, Sweden, and conducted his post-doctoral fellowship under Tony Hunter at the Salk Institute.

Roles

Acrivon Therapeutics, Inc.
Co-Founder, Chief Executive Officer, President & Chairman · Current role
March 2018–present
Acrivon Therapeutics, Inc.
Founder, CEO, President & acting CSO
March 2018 - present
XTuit Pharmaceuticals
Chief Scientific Officer
2014 - 2018
Metamark Genetics
Chief Scientific Officer
2010 - 2014
Daiichi Sankyo, Inc.
Vice President, External Scientific Affairs & Global Therapeutic Area Advisor, Oncology
2008 - 2010
Merck & Co., Inc.
Department Head, Oncology
2001 - 2008
Serono, US
Department Head
—

Fixed Compensation

FY 2025
Salary
$709,893
ComponentAnnual base salary earned in 2025
All other compensation
$6,000
ComponentEmployer 401(k) matching contributions
Total compensation
$2,718,538

Performance Compensation

Data from FY 2025

Cash incentive

Non-equity incentive plan compensation
$410,400
Target Opportunity
—
PlanAnnual performance-based cash incentive

Stock awards

Option awards
$1,592,245
FormStock options, ASC 718 grant-date fair value

Also at Acrivon Therapeutics, Inc.

Related

See how Top Bucket AI works for your firm

Request Demo
Top Bucket AI Research

Stay ahead of private markets

Research and market intelligence for private-markets professionals.

✓

You're subscribed.

Thanks for signing up.